Free Trial
→ Silicon Valley Gold Rush (From Stansberry Research) (Ad)
NASDAQ:AIMD

Ainos Q2 2024 Earnings Report

Ainos logo
$0.50 -0.04 (-8.03%)
As of 06/13/2025 04:00 PM Eastern
ProfileEarnings History

Ainos EPS Results

Actual EPS
-$0.49
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Ainos Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ainos Announcement Details

Quarter
Q2 2024
Date
8/5/2024
Time
N/A
Conference Call Date
Monday, August 5, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Ainos' Q2 2025 earnings is scheduled for Monday, August 4, 2025

Conference Call Resources

Powered by Quartr

Earnings Documents

Ainos' Q2 2024 Press ReleasePress Release
(8-K)
Ainos' Q2 2024 Quarterly reportQuarterly report
(10-Q)

Ainos Earnings Headlines

Ainos, Inc.: Ainos AI Nose Improves Accuracy in Hygiene Monitoring To 85% from 80%
May 29, 2025 | finanznachrichten.de
Ainos, Inc.: Ainos Reports Breakthrough Interim Results in VELDONA Clinical Trial for FCGS, Signaling New Era in Companion Animal Immunotherapy
May 20, 2025 | finanznachrichten.de
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
June 14, 2025 | Stansberry Research (Ad)
Ainos, Inc.: Water Tower Research Spotlights Ainos' Smell Integration in Humanoid Robot - AI Smelltech is Progressing Rapidly
April 24, 2025 | finanznachrichten.de
Ainos, Inc.: Water Tower Research Highlights Ainos' AI Nose Expansion into Robotics and Semiconductor Manufacturing - Smell ID Is Scaling
April 11, 2025 | finanznachrichten.de
Water Tower Research Spotlights Ainos & ASE Partnership: Unleashing AI Nose’s Potential in Chip Manufacturing and More
March 13, 2025 | finance.yahoo.com
See More Ainos Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ainos? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ainos and other key companies, straight to your email.

About Ainos

Ainos (NASDAQ:AIMD), a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

View Ainos Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles